Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 11/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 8/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641149 | 0.99 | EGLN3 (0.52) | EGLN3EGLN1CNR1CNR2EGLN2 | |
| SCHEMBL12727520 | 0.89 | EGLN3 (0.52) | EGLN3EGLN1EGLN2CYSLTR2PPARG | |
| SCHEMBL1641745 | 0.88 | EGLN3 (0.54) | EGLN3EGLN1EGLN2CYSLTR2 | |
| SCHEMBL1642989 | 0.87 | EGLN3 (0.55) | EGLN3EGLN1EGLN2CYSLTR2 | |
| SCHEMBL1641922 | 0.86 | EGLN3 (0.58) | EGLN3EGLN1CNR1CNR2EGLN2 | |
| SCHEMBL1640596 | 0.85 | EGLN3 (0.57) | EGLN3EGLN1CNR1CNR2EGLN2 | |
| SCHEMBL1640582 | 0.85 | EGLN3 (0.55) | EGLN3EGLN1CNR1CNR2EGLN2 | |
| SCHEMBL1641891 | 0.85 | EGLN3 (0.55) | EGLN3EGLN1CNR1CNR2EGLN2 | |
| SCHEMBL1641889 | 0.85 | EGLN3 (0.59) | EGLN3EGLN1EGLN2CYSLTR2PPARG | |
| SCHEMBL12727514 | 0.85 | EGLN3 (0.59) | EGLN3EGLN1EGLN2CYSLTR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| WO-2009158315-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN3 3/4885EGLN1 6/4885CNR1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.